Mostrar el registro sencillo del ítem

dc.contributor.authorSosa, Nestor
dc.contributor.authorCapitan, Zeuz
dc.contributor.authorNieto, Javier
dc.contributor.authorNieto, Melissa
dc.contributor.authorCalzada, Jose
dc.contributor.authorPaz, Hector
dc.contributor.authorSpadafora, Carmenza
dc.contributor.authorKreishman-Deitrick, Mara
dc.contributor.authorKopydlowski, Karen
dc.contributor.authorUllman, Diane
dc.contributor.authorMcCarthy, William F.
dc.contributor.authorRansom, Janet
dc.contributor.authorBerman, Jonathan
dc.contributor.authorScott, Charles
dc.contributor.authorGrogl, Max
dc.date.accessioned2020-06-20T03:58:55Z
dc.date.available2020-06-20T03:58:55Z
dc.date.issued2013-07-15
dc.identifier.otherdoi:10.4269/ajtmh.12-0736
dc.identifier.urihttp://repositorio-indicasat.org.pa/handle/123456789/100
dc.descriptionIn this randomized, double-blinded Phase 2 trial, 30 patients with Leishmania panamensis cutaneous leishmaniasis were randomly allocated (1:1) to receive once daily topical treatment with WR 279,396 (15% paromomycin + 0.5% gentamicin) or Paromomycin Alone (15% paromomycin) for 20 days. The index lesion cure rate after 6 months follow-up was 13 of 15 (87%) for WR 279,396 and 9 of 15 (60%) for Paromomycin Alone (P = 0.099). When all treated lesions were included, the final cure rate for WR 279,398-treated patients was again 87%, but the final cure rate for Paromomycin Alone-treated patients was 8 of 15 (53.3%; P = 0.046). Both creams were well tolerated with mild application site reactions being the most frequent adverse event. The increased final cure rate in the WR 279,396 group in this small Phase 2 study suggests that the combination product may provide greater clinical benefit than paromomycin monotherapy against L. panamensis cutaneous leishmaniasisen_US
dc.description.abstractIn this randomized, double-blinded Phase 2 trial, 30 patients with Leishmania panamensis cutaneous leishmaniasis were randomly allocated (1:1) to receive once daily topical treatment with WR 279,396 (15% paromomycin + 0.5% gentamicin) or Paromomycin Alone (15% paromomycin) for 20 days. The index lesion cure rate after 6 months follow-up was 13 of 15 (87%) for WR 279,396 and 9 of 15 (60%) for Paromomycin Alone (P = 0.099). When all treated lesions were included, the final cure rate for WR 279,398-treated patients was again 87%, but the final cure rate for Paromomycin Alone-treated patients was 8 of 15 (53.3%; P = 0.046). Both creams were well tolerated with mild application site reactions being the most frequent adverse event. The increased final cure rate in the WR 279,396 group in this small Phase 2 study suggests that the combination product may provide greater clinical benefit than paromomycin monotherapy against L. panamensis cutaneous leishmaniasisen_US
dc.formatapplication/pdf
dc.language.isoengen_US
dc.rightsInfo:eu-repo/semantics/openAccess
dc.rightshttps://creativecommons.org/licenses/by/4.0/
dc.subjectRandomizeden_US
dc.subjectDouble-Blindeden_US
dc.subjectCutaneous Leishmaniasis in Panamaen_US
dc.titleRandomized, Double-Blinded, Phase 2 Trial of WR 279,396 (Paromomycin and Gentamicin) for Cutaneous Leishmaniasis in Panamaen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeInfo:eu-repo/semantics/publishedversion


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem